PainReform Ltd. (NASDAQ:PRFX) Sees Large Decline in Short Interest

PainReform Ltd. (NASDAQ:PRFX – Get Free Report) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 47,016 shares, a drop of 76.6% from the August 15th total of 200,670 shares. Approximately 8.2% of the shares of the stock are sold short. Based on an average trading volume of 74,557 shares, the days-to-cover ratio is presently 0.6 days.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PRFX. Wall Street Zen upgraded PainReform to a “sell” rating in a research note on Saturday, August 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of PainReform in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, PainReform presently has an average rating of “Sell”.

Get PainReform alerts:

Check Out Our Latest Stock Report on PainReform

PainReform Price Performance

PRFX stock traded down $0.07 during trading on Friday, reaching $0.86. 88,064 shares of the company were exchanged, compared to its average volume of 106,769. The company has a 50-day moving average of $1.08 and a two-hundred day moving average of $1.74. The company has a market capitalization of $747,426.90, a price-to-earnings ratio of -0.00 and a beta of 1.05. PainReform has a twelve month low of $0.85 and a twelve month high of $7.95.

PainReform (NASDAQ:PRFX – Get Free Report) last issued its earnings results on Thursday, September 3rd. The company reported ($1.13) earnings per share for the quarter. The business had revenue of $0.01 million for the quarter.

About PainReform

(Get Free Report)

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.

See Also

• Five stocks we like better than PainReform
• Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
• Optical Cable Corporation Is Starting to Get the Market’s Attention
• Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
• Is Nike’s Index Demotion a Warning or a Buying Opportunity?

Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.